Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials.
Dig Dis SciJun 18, 2026 (epub)
Samira Mohamad Khalil, Lubna Al-Sharif, Ivanna Diaz et al.
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis evaluated the incidence of cirrhosis in placebo-treated patients with fibrotic metabolic dysfunction-associated steatohepatitis (MASH) across 11 randomized controlled trials. Among 586 patients, the pooled incidence rate of cirrhosis was 13.09 per 100 person-years. Notably, the incidence was significantly higher in patients with MASH F3 compared to F2.
Key findings
- The pooled incidence rate of cirrhosis was 13.09 per 100 person-years.
- Incidence in MASH F2 was 3.40 per 100 person-years.
- Incidence in MASH F3 was 17.90 per 100 person-years.
- Significant differences in cirrhosis incidence were observed between MASH F2 and F3 (p=0.006).
Why it matters
Understanding the incidence of cirrhosis in patients with fibrotic MASH is crucial for clinicians to assess the short-term risks associated with different fibrosis stages, which can influence treatment decisions and patient management strategies.